vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and RGC RESOURCES INC (RGCO). Click either name above to swap in a different company.

RGC RESOURCES INC is the larger business by last-quarter revenue ($30.6M vs $19.6M, roughly 1.6× STANDARD BIOTOOLS INC.). RGC RESOURCES INC runs the higher net margin — 16.0% vs -177.4%, a 193.4% gap on every dollar of revenue. On growth, RGC RESOURCES INC posted the faster year-over-year revenue change (13.9% vs -11.5%). RGC RESOURCES INC produced more free cash flow last quarter ($-4.6M vs $-23.1M). Over the past eight quarters, RGC RESOURCES INC's revenue compounded faster (-0.4% CAGR vs -12.2%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Iluka Resources is an Australian resources company, specialising in mineral sands exploration, project development, operations and marketing. It was formed in July 1998 in a merger between Westralian Sands and the titanium mineral business RGC Ltd, becoming Iluka Resources Ltd in 1999. Iluka is a major producer of zircon and titanium dioxide–derived rutile and synthetic rutile globally. The company has operations in Australia, and has also conducted business in the United States and the West ...

LAB vs RGCO — Head-to-Head

Bigger by revenue
RGCO
RGCO
1.6× larger
RGCO
$30.6M
$19.6M
LAB
Growing faster (revenue YoY)
RGCO
RGCO
+25.4% gap
RGCO
13.9%
-11.5%
LAB
Higher net margin
RGCO
RGCO
193.4% more per $
RGCO
16.0%
-177.4%
LAB
More free cash flow
RGCO
RGCO
$18.5M more FCF
RGCO
$-4.6M
$-23.1M
LAB
Faster 2-yr revenue CAGR
RGCO
RGCO
Annualised
RGCO
-0.4%
-12.2%
LAB

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
LAB
LAB
RGCO
RGCO
Revenue
$19.6M
$30.6M
Net Profit
$-34.7M
$4.9M
Gross Margin
48.5%
Operating Margin
-168.5%
21.4%
Net Margin
-177.4%
16.0%
Revenue YoY
-11.5%
13.9%
Net Profit YoY
-28.8%
-7.3%
EPS (diluted)
$-0.09
$0.47

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
RGCO
RGCO
Q4 25
$30.6M
Q3 25
$19.6M
$14.0M
Q2 25
$21.8M
$16.6M
Q1 25
$40.8M
$36.5M
Q4 24
$26.8M
Q3 24
$22.1M
$12.8M
Q2 24
$22.5M
$13.6M
Q1 24
$45.5M
$30.8M
Net Profit
LAB
LAB
RGCO
RGCO
Q4 25
$4.9M
Q3 25
$-34.7M
$-204.3K
Q2 25
$-33.5M
$538.4K
Q1 25
$-26.0M
$7.7M
Q4 24
$5.3M
Q3 24
$-26.9M
$140.8K
Q2 24
$-45.7M
$156.7K
Q1 24
$-32.2M
$6.4M
Gross Margin
LAB
LAB
RGCO
RGCO
Q4 25
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
LAB
LAB
RGCO
RGCO
Q4 25
21.4%
Q3 25
-168.5%
-3.4%
Q2 25
-118.1%
7.2%
Q1 25
-80.8%
28.5%
Q4 24
27.3%
Q3 24
-120.9%
1.9%
Q2 24
-134.5%
11.5%
Q1 24
-132.2%
28.0%
Net Margin
LAB
LAB
RGCO
RGCO
Q4 25
16.0%
Q3 25
-177.4%
-1.5%
Q2 25
-153.7%
3.2%
Q1 25
-63.8%
21.1%
Q4 24
19.6%
Q3 24
-122.0%
1.1%
Q2 24
-203.3%
1.2%
Q1 24
-70.6%
20.9%
EPS (diluted)
LAB
LAB
RGCO
RGCO
Q4 25
$0.47
Q3 25
$-0.09
$-0.01
Q2 25
$-0.09
$0.05
Q1 25
$-0.07
$0.74
Q4 24
$0.51
Q3 24
$-0.07
$0.01
Q2 24
$-0.12
$0.02
Q1 24
$-0.27
$0.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
RGCO
RGCO
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$399.7M
$116.4M
Total Assets
$539.6M
$341.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
RGCO
RGCO
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
LAB
LAB
RGCO
RGCO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
RGCO
RGCO
Q4 25
$116.4M
Q3 25
$399.7M
$113.6M
Q2 25
$424.5M
$116.3M
Q1 25
$454.6M
$117.8M
Q4 24
$111.8M
Q3 24
$489.3M
$108.1M
Q2 24
$510.3M
$108.8M
Q1 24
$577.3M
$110.5M
Total Assets
LAB
LAB
RGCO
RGCO
Q4 25
$341.0M
Q3 25
$539.6M
$329.8M
Q2 25
$557.0M
$324.8M
Q1 25
$579.6M
$326.4M
Q4 24
$335.2M
Q3 24
$681.5M
$320.7M
Q2 24
$708.7M
$314.2M
Q1 24
$777.7M
$313.4M
Debt / Equity
LAB
LAB
RGCO
RGCO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
RGCO
RGCO
Operating Cash FlowLast quarter
$-22.2M
$1.1M
Free Cash FlowOCF − Capex
$-23.1M
$-4.6M
FCF MarginFCF / Revenue
-118.1%
-14.9%
Capex IntensityCapex / Revenue
4.5%
18.5%
Cash ConversionOCF / Net Profit
0.22×
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
RGCO
RGCO
Q4 25
$1.1M
Q3 25
$-22.2M
$675.1K
Q2 25
$-20.7M
$6.4M
Q1 25
$-30.3M
$21.0M
Q4 24
$827.2K
Q3 24
$-27.9M
$377.4K
Q2 24
$-39.0M
$5.9M
Q1 24
$-62.5M
$11.8M
Free Cash Flow
LAB
LAB
RGCO
RGCO
Q4 25
$-4.6M
Q3 25
$-23.1M
Q2 25
$-22.6M
$1.4M
Q1 25
$-35.3M
$16.1M
Q4 24
$-4.9M
Q3 24
$-30.1M
$-5.1M
Q2 24
$-41.0M
$564.7K
Q1 24
$-63.3M
$5.8M
FCF Margin
LAB
LAB
RGCO
RGCO
Q4 25
-14.9%
Q3 25
-118.1%
Q2 25
-103.6%
8.4%
Q1 25
-86.6%
44.1%
Q4 24
-18.3%
Q3 24
-136.4%
-40.2%
Q2 24
-182.2%
4.2%
Q1 24
-138.9%
18.8%
Capex Intensity
LAB
LAB
RGCO
RGCO
Q4 25
18.5%
Q3 25
4.5%
Q2 25
8.7%
30.4%
Q1 25
12.4%
13.6%
Q4 24
21.4%
Q3 24
10.2%
43.2%
Q2 24
8.6%
39.0%
Q1 24
1.7%
19.4%
Cash Conversion
LAB
LAB
RGCO
RGCO
Q4 25
0.22×
Q3 25
Q2 25
11.96×
Q1 25
2.74×
Q4 24
0.16×
Q3 24
2.68×
Q2 24
37.36×
Q1 24
1.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

RGCO
RGCO

Segment breakdown not available.

Related Comparisons